RDS-127 induces biphasic dose-related changes in spontaneous locomotor activity in rats, similar to the reported effects of APO. Compared to APO, RDS-127 demonstrates a more potent stimulation of movement, with an efficacy that is tripled and lasts four times longer. In terms of selectivity, RDS-127 clearly outperforms APO, showing a preference for activating DA autoreceptors in the nigrostriatal pathway rather than postsynaptic DA receptors.